Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACOR | Acorda Therapeutics, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA | NASD
Scroll to Statements
Index- P/E- EPS (ttm)-17.09 Insider Own0.10% Shs Outstand1.24M Perf Week5.05%
Market Cap20.29M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.23M Perf Month-5.39%
Income-20.90M PEG- EPS next Q- Inst Own25.80% Short Float / Ratio0.55% / 0.72 Perf Quarter21.86%
Sales116.90M P/S0.17 EPS this Y65.80% Inst Trans-53.95% Short Interest0.01M Perf Half Y26.91%
Book/sh54.64 P/B0.29 EPS next Y- ROA-5.50% Target Price- Perf Year123.96%
Cash/sh19.46 P/C0.80 EPS next 5Y46.00% ROE-26.60% 52W Range5.22 - 24.80 Perf YTD1.80%
Dividend- P/FCF- EPS past 5Y34.30% ROI-14.90% 52W High-37.06% Beta1.38
Dividend %- Quick Ratio1.60 Sales past 5Y-27.40% Gross Margin81.30% 52W Low198.93% ATR1.17
Employees111 Current Ratio2.10 Sales Q/Q-4.50% Oper. Margin6.30% RSI (14)56.22 Volatility5.39% 8.97%
OptionableNo Debt/Eq2.59 EPS Q/Q86.40% Profit Margin-17.90% Rel Volume2.82 Prev Close15.80
ShortableYes LT Debt/Eq2.59 EarningsAug 08 AMC Payout- Avg Volume9.39K Price15.61
Recom2.00 SMA2011.24% SMA502.71% SMA20010.01% Volume26,467 Change-1.20%
Date Action Analyst Rating Change Price Target Change
Jun-17-21Upgrade H.C. Wainwright Neutral → Buy $5 → $10
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Show Previous Ratings
Aug-28-23 12:42PM
Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market Value
(GuruFocus.com) -10.09%
Aug-08-23 04:21PM
Acorda: Q2 Earnings Snapshot
(AP Finance) -6.25%
04:01PM
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
(Business Wire)
Aug-02-23 08:00AM
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters"
(Business Wire)
Aug-01-23 08:00AM
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
(Business Wire)
05:08PM Loading…
Jun-28-23 05:08PM
Tom Burns Elected to the Acorda Therapeutics Board of Directors
(Business Wire) +5.71%
Jun-26-23 08:23AM
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
(Business Wire)
Jun-05-23 09:06AM
Little Excitement Around Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Revenues
(Simply Wall St.)
Jun-02-23 04:01PM
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
(Business Wire) -9.35%
May-31-23 04:01PM
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
(Business Wire)
May-30-23 08:00AM
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
(Business Wire)
May-12-23 05:28AM
Q1 2023 Acorda Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -17.25%
May-11-23 04:29PM
Acorda: Q1 Earnings Snapshot
(AP Finance)
04:01PM
Acorda Therapeutics Reports First Quarter 2023 Financial Results
(Business Wire)
02:26PM
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
(InvestorPlace)
07:00AM Loading…
May-10-23 07:00AM
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
(Business Wire)
May-08-23 07:00AM
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
(Business Wire) +77.78%
May-04-23 09:41AM
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
(Business Wire)
Apr-24-23 08:00AM
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
(Business Wire)
Apr-03-23 08:00AM
Acorda Launches INBRIJA® TV Commercial for Parkinsons Awareness Month
(Business Wire)
Mar-27-23 08:00AM
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
(Business Wire)
Mar-09-23 07:00AM
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
(Business Wire) -18.73%
Mar-07-23 07:00AM
ESTEVE Launches INBRIJA® in Spain
(Business Wire)
Mar-06-23 03:43PM
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
(Business Wire)
Feb-14-23 04:46PM
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
(Business Wire)
Jan-31-23 04:01PM
Acorda Therapeutics to Present at Sequire Biotechnology Conference
(Business Wire) +6.42%
Jan-05-23 04:20PM
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
(Business Wire) -10.89%
Dec-22-22 08:00AM
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
(Business Wire)
Dec-20-22 05:30PM
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
(Business Wire)
Dec-05-22 07:01AM
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
(Business Wire)
08:12AM Loading…
Nov-19-22 08:12AM
Acorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)
(Simply Wall St.)
Nov-11-22 09:52AM
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
(Business Wire) +12.44%
Nov-04-22 09:25AM
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
(Business Wire)
Nov-01-22 04:01PM
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
(Business Wire) -25.22%
Oct-27-22 07:00AM
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
(Business Wire) +21.72%
Oct-25-22 04:01PM
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
(Business Wire)
Oct-21-22 07:00AM
Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
(Business Wire)
Oct-19-22 07:00AM
ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
(Business Wire) -20.27%
Oct-18-22 07:00AM
Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
(Business Wire) -18.62%
Oct-16-22 04:48PM
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
(Business Wire)
Oct-10-22 06:30AM
Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders
(Business Wire)
Sep-08-22 04:01PM
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
(Business Wire) +6.38%
Aug-29-22 07:00AM
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
(Business Wire)
Aug-19-22 08:00AM
Acorda Therapeutics Announces Resignation of Chief Operating Officer
(Business Wire)
Aug-04-22 04:01PM
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
(Business Wire) +12.69%
Jul-28-22 04:01PM
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
(Business Wire)
Jun-16-22 09:31AM
Why Acorda Therapeutics Shares Gaining Today?
(Benzinga) +54.47%
07:01AM
Esteve Launches INBRIJA® in Germany
(Business Wire)
May-11-22 04:01PM
Acorda Therapeutics Reports First Quarter 2022 Financial Results
(Business Wire) -10.27%
04:01PM
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
(Business Wire)
May-04-22 04:01PM
Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
(Business Wire) -5.34%
Mar-09-22 04:01PM
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
(Business Wire)
Feb-24-22 05:00PM
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
(Business Wire)
Jan-04-22 07:11AM
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
(Business Wire)
Jan-03-22 04:01PM
John Varian Joins Acorda Therapeutics Board of Directors
(Business Wire)
Nov-09-21 04:01PM
Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team
(Business Wire)
04:01PM
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
(Business Wire)
Nov-02-21 07:00AM
Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021
(Business Wire)
Sep-09-21 08:01AM
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
(Business Wire)
Aug-05-21 05:45PM
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
(Zacks) +9.33%
04:01PM
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
(Business Wire)
Jul-30-21 04:01PM
Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
(Business Wire) -5.06%
Jul-27-21 03:02PM
Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know
(Zacks) -7.69%
Jul-23-21 07:28AM
Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
(InvestorPlace) +24.15%
Jul-22-21 04:01PM
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
(Business Wire)
Jun-18-21 10:46PM
Hedge Funds Are Buying Acorda Therapeutics Inc (ACOR) Again
(Insider Monkey) -8.04%
Jun-16-21 07:00AM
Acorda Therapeutics Announces Repayment of Convertible Senior Notes
(Business Wire)
May-06-21 05:15PM
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
04:00PM
Acorda Therapeutics Reports First Quarter 2021 Financial Results
(Business Wire)
Apr-29-21 04:30PM
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
(Business Wire)
Apr-27-21 12:00PM
All You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy
(Zacks)
Apr-20-21 09:46AM
J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales
(Zacks)
Apr-12-21 07:00AM
Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of "A Taste for Life with Zarela"
(Business Wire)
Apr-01-21 07:51AM
QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA
(Zacks)
Mar-12-21 10:01AM
Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes
(Zacks)
Mar-11-21 08:52AM
Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
(Zacks) +5.01%
Mar-10-21 11:30AM
Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?
(Zacks)
Mar-08-21 11:12PM
The Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Just Boosted Their Forecasts By A Dazzling Amount
(Simply Wall St.)
05:44PM
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
(Business Wire)
Mar-05-21 08:15AM
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
(Benzinga) -23.01%
Mar-04-21 05:45PM
Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates
(Zacks) +7.79%
04:01PM
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
(Business Wire)
Mar-03-21 12:52PM
Encompass Health (EHC) Ties Up for Better Homehealth Care
(Zacks)
Mar-02-21 08:43AM
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
(Zacks)
Feb-26-21 10:10AM
Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall
(Zacks)
Feb-25-21 07:00AM
Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
(Business Wire)
Feb-19-21 07:00AM
Acorda Therapeutics Announces Departure of Chief, Business Operations
(Business Wire)
Feb-11-21 11:12AM
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
(Zacks)
09:13AM
Sesen Bio (SESN) Surges: Stock Moves 6.4% Higher
(Zacks)
07:00AM
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
(Business Wire)
Feb-10-21 10:21AM
Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss
(Zacks) -5.85%
Feb-08-21 12:40PM
Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
(Zacks)
Feb-04-21 11:48AM
Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates
(Zacks)
Feb-02-21 03:23PM
Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B
(Zacks)
10:10AM
Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes
(Zacks)
Feb-01-21 10:28AM
Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib
(Zacks)
10:25AM
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase
(Zacks)
09:36AM
Illumina (ILMN) New Collaboration to Aid Genomics Startups
(Zacks)
Jan-28-21 10:12AM
Global Blood's (GBT) MAA for Oxbryta Accepted in Europe
(Zacks)
Jan-27-21 11:13AM
Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA
(Zacks)
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COHEN RONPresident and CEOMar 17Buy0.6510,0006,500149,757Mar 20 04:29 PM
COHEN RONPresident and CEOMar 16Buy0.6010,1566,094139,757Mar 20 04:29 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2023 FINVIZ.com. All Rights Reserved.